| HOME >> MEDICINE >> TECHNOLOGY |
1,059,000
(146,000)
(50,000)863,000Research and development
534,000
(14,000)
(1,000)519,000Selling and marketing
3,725,000
(87,000)
(13,000)3,625,000Amortization
216,000$(216,000)
-5,534,000
(247,000)
(64,000)
(216,000)
5,007,000Operating Loss
$(678,000)
$255,000
$72,000
$216,000
$(135,000)December 31, 2011Gross Profit
$4,568,000
$6,000
$9,000$4,583,000% of net sales
85.5%85.8%Operating ExpensesGeneral and administrative
925,000
(132,000)
(40,000)753,000Research and development
586,000
(11,000)
(2,000)573,000Selling and marketing
3,903,000
(62,000)
(14,000)3,827,000Amortization
215,000$(215,000)
-5,629,000
(205,000)
(56,000)
(215,000)
5,153,000Operating Loss
$(1,061,000)
$211,000
$65,000
$215,000
$(570,000)
Expense AdjustmentsNine-Months EndedGAAPShare-based ExpenseDepreciationAmortization of IntangiblesNon-GAAPDecember 31, 2012Gross Profit
$14,613,000
$23,000
$26,000$14,662,000% of net sales
86.6%86.9%Operating ExpensesGeneral and administrative
3,178,000
(340,000)
(146,000)2,692,000Research and development
1,696,000
(40,000)
(2,000)1,654,000Selling and marketing
11,425,000
(208,000)
(43,000)11,174,000Amortization
647,000$(647,000)
-16,946,000
(588,000)
(191,000)
(647,000)
15,520,000Operating Loss
$(2,333,000)
$611,000
$217,000
$647,000
$(858,000)December 31, 2011Gross Profit
$12,720,000
$16
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2012 PR Newswire. All rights reserved |